Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.25 +0.1%	$57.88	$52.93 ▼ $94.85	$10.98B	0.17	1.73 million shs	1.38 million shs
FGEN FibroGen	$5.69 +8.4%	$7.16	$4.50 ▼ $38.25	$22.99M	0.74	75,476 shs	33,072 shs
PFE Pfizer	$25.45 +0.5%	$23.72	$20.92 ▼ $31.54	$144.66B	0.58	41.56 million shs	27.10 million shs
PTC PTC	$175.13 +1.0%	$167.75	$133.38 ▼ $203.09	$21.01B	1.17	891,278 shs	468,442 shs
SRPT Sarepta Therapeutics	$18.22 +0.1%	$35.34	$16.88 ▼ $154.90	$1.79B	0.45	2.18 million shs	2.48 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	0.00%	+3.77%	+1.06%	-3.23%	-29.71%
FGEN FibroGen	0.00%	+9.00%	-27.35%	-16.66%	-68.46%
PFE Pfizer	0.00%	+5.16%	+8.93%	+12.39%	-9.29%
PTC PTC	0.00%	+3.44%	+2.81%	+25.37%	-6.08%
SRPT Sarepta Therapeutics	0.00%	+6.46%	-57.65%	-65.24%	-88.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMRN BioMarin Pharmaceutical	4.9421 of 5 stars	3.4	3.0	0.0	3.3	2.7	2.5	4.4
FGEN FibroGen	4.7129 of 5 stars	3.3	3.0	0.0	4.7	4.4	3.3	0.6
PFE Pfizer	4.9799 of 5 stars	3.2	3.0	4.2	4.5	2.8	1.7	3.1
PTC PTC	3.8839 of 5 stars	2.2	2.0	0.0	2.8	2.9	2.5	1.9
SRPT Sarepta Therapeutics	4.7381 of 5 stars	4.2	2.0	0.0	4.2	2.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$93.61	63.51% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	4,293.67% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside
PTC PTC	2.46	Hold	$188.69	7.75% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$60.88	234.20% Upside

Current Analyst Ratings Breakdown

Latest BMRN, PFE, PTC, SRPT, and FGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$97.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$2.85B	3.85	$3.23 per share	17.71	$29.69 per share	1.93
FGEN FibroGen	$29.62M	0.78	N/A	N/A	($50.89) per share	-0.11
PFE Pfizer	$63.63B	2.27	$4.37 per share	5.82	$15.62 per share	1.63
PTC PTC	$2.30B	9.14	$4.83 per share	36.26	$26.76 per share	6.54
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.43 per share	7.49	$15.99 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	21.28	13.13	0.79	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
PTC PTC	$376.33M	$3.64	48.11	32.25	2.41	18.77%	15.35%	7.97%	7/30/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.66	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest BMRN, PFE, PTC, SRPT, and FGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	BMRN BioMarin Pharmaceutical	$1.02	N/A	N/A	N/A	$761.51 million	N/A
7/30/2025	Q3 2025	PTC PTC	$1.22	N/A	N/A	N/A	$582.12 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
4/30/2025	Q2 2025	PTC PTC	$1.37	$1.79	+$0.42	$1.35	$608.64 million	$636.37 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years
PTC PTC	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest BMRN, PFE, PTC, SRPT, and FGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
FGEN FibroGen	N/A	2.02	1.98
PFE Pfizer	0.64	1.26	0.96
PTC PTC	0.40	0.99	0.99
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
FGEN FibroGen	72.71%
PFE Pfizer	68.36%
PTC PTC	95.14%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.85%
FGEN FibroGen	1.98%
PFE Pfizer	0.06%
PTC PTC	0.32%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
FGEN FibroGen	570	4.04 million	3.96 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
PTC PTC	7,501	119.95 million	119.56 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

BMRN, PFE, PTC, SRPT, and FGEN Headlines

Recent News About These Companies

INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

1 hour ago | prnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Allspring Global Investments Holdings LLC

2 hours ago | marketbeat.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 6 at 8:15 AM | globenewswire.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, ...

July 5 at 6:27 PM | gurufocus.com

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

July 5 at 2:31 PM | markets.businessinsider.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 5 at 11:40 AM | globenewswire.com

Braun Stacey Associates Inc. Has $4.20 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

July 5 at 8:41 AM | marketbeat.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, ...

July 4 at 4:31 PM | gurufocus.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 4 at 4:00 PM | globenewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. ...

July 4 at 9:12 AM | gurufocus.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 4 at 8:23 AM | globenewswire.com

Robbins LLP Files Class Action Against Sarepta Therapeutics Over ELEVIDYS Deaths

July 4 at 6:48 AM | lawyer-monthly.comL

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the ...

July 3, 2025 | gurufocus.com

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

July 3, 2025 | globenewswire.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations -- Investors Should Contact Levi ...

July 3, 2025 | gurufocus.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT

July 3, 2025 | globenewswire.com

SRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit

July 3, 2025 | businesswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

July 3, 2025 | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 3, 2025 | prnewswire.com

Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

July 2, 2025 | globenewswire.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

July 2, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN, PFE, PTC, SRPT, and FGEN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$57.25 +0.08 (+0.14%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$57.24 -0.01 (-0.01%)

As of 04:03 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

FibroGen NASDAQ:FGEN

$5.69 +0.44 (+8.38%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$5.54 -0.15 (-2.62%)

As of 04:24 AM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$25.34 -0.11 (-0.42%)

As of 04:48 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PTC NASDAQ:PTC

$175.12 +1.82 (+1.05%)

Closing price 07/3/2025 02:54 PM Eastern

Extended Trading

$175.12 0.00 (0.00%)

As of 04:37 AM Eastern

PTC Inc. operates as software company in the Americas, Europe, and the Asia Pacific. The company provides Windchill, a suite that manages all aspects of the product development lifecycle(PLM) that provides real-time information sharing, dynamic data visualization, collaborate across geographically distributed teams, and enabling manufacturers to elevate product development, manufacturing, and field service processes; ThingWorx, a platform for Industrial Internet of Things; ServiceMax, a field service management solutions enable companies to asset uptime with optimized in-person and remote service and technician productivity with mobile tools. and deliver metrics; and Arena, a SaaS PLM solution enables product teams to collaborate virtually to share product and quality information with internal teams and supply chain partners and deliver products to customers. It offers Codebeamer, an application lifecycle management for products and software development; Servigistics, a service parts management solution; and FlexPLM, a solution provides retailers with a single platform for merchandising and line planning, materials management, sampling, and others. In addition, it offers Kepware, a portfolio of industrial connectivity solutions helps companies connect diverse automation devices and software applications; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Onshape, a cloud product development platform that delivers computer-aided design with data management tools. Further, it offers Vuforia, an augmented reality (AR) technology enables the visualization of digital information in a physical context and the creation of AR enabling companies to drive results in manufacturing, service, engineering, and operations; and Arbortext, a dynamic publishing solution streamlines how organizations create, manage, and publish technical documentation. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$18.22 +0.03 (+0.14%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$18.24 +0.03 (+0.16%)

As of 04:48 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time